Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 3
2006 2
2007 1
2008 3
2009 2
2010 1
2011 5
2012 1
2013 1
2014 2
2015 4
2016 3
2017 7
2018 6
2019 7
2020 9
2021 7
2022 7
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
Precision oncology for RET-related tumors.
Verrienti A, Grani G, Sponziello M, Pecce V, Damante G, Durante C, Russo D, Filetti S. Verrienti A, et al. Front Oncol. 2022 Aug 24;12:992636. doi: 10.3389/fonc.2022.992636. eCollection 2022. Front Oncol. 2022. PMID: 36091144 Free PMC article. Review.
Thyroid hormone therapy in differentiated thyroid cancer.
Grani G, Ramundo V, Verrienti A, Sponziello M, Durante C. Grani G, et al. Among authors: verrienti a. Endocrine. 2019 Oct;66(1):43-50. doi: 10.1007/s12020-019-02051-3. Epub 2019 Oct 15. Endocrine. 2019. PMID: 31617165 Review.
XL184 (cabozantinib) for medullary thyroid carcinoma.
Durante C, Russo D, Verrienti A, Filetti S. Durante C, et al. Among authors: verrienti a. Expert Opin Investig Drugs. 2011 Mar;20(3):407-413. doi: 10.1517/13543784.2011.559163. Expert Opin Investig Drugs. 2011. PMID: 21314233 Review.
Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside.
Sarno F, Benincasa G, List M, Barabasi AL, Baumbach J, Ciardiello F, Filetti S, Glass K, Loscalzo J, Marchese C, Maron BA, Paci P, Parini P, Petrillo E, Silverman EK, Verrienti A, Altucci L, Napoli C; International Network Medicine Consortium. Sarno F, et al. Among authors: verrienti a. Clin Epigenetics. 2021 Mar 30;13(1):66. doi: 10.1186/s13148-021-01047-z. Clin Epigenetics. 2021. PMID: 33785068 Free PMC article. Review.
Circulating cell-free DNA (cfDNA) in patients with medullary thyroid carcinoma is characterized by specific fragmentation and methylation changes with diagnostic value.
Citarella A, Besharat ZM, Trocchianesi S, Autilio TM, Verrienti A, Catanzaro G, Splendiani E, Spinello Z, Cantara S, Zavattari P, Loi E, Romei C, Ciampi R, Pezzullo L, Castagna MG, Angeloni A, Elisei R, Durante C, Po A, Ferretti E. Citarella A, et al. Among authors: verrienti a. Biomark Res. 2023 Sep 19;11(1):82. doi: 10.1186/s40364-023-00522-4. Biomark Res. 2023. PMID: 37726827 Free PMC article.
Molecular mechanisms of the tyrosine kinase inhibitor pralsetinib activity in in-vitro models of medullary thyroid carcinoma: Aberrant activation of the HH-Gli signaling pathway in acquired resistance.
Trocchianesi S, Po A, Citarella A, Spinello Z, Rughetti A, Besharat ZM, Autilio TM, Pecce V, Verrienti A, Elisei R, Durante C, Catanzaro G, Ferretti E. Trocchianesi S, et al. Among authors: verrienti a. Biomed Pharmacother. 2023 Aug;164:114995. doi: 10.1016/j.biopha.2023.114995. Epub 2023 Jun 8. Biomed Pharmacother. 2023. PMID: 37301138 Free article.
Expression of YAP1 in aggressive thyroid cancer.
Celano M, Mignogna C, Rosignolo F, Sponziello M, Iannone M, Lepore SM, Lombardo GE, Maggisano V, Verrienti A, Bulotta S, Durante C, Di Loreto C, Damante G, Russo D. Celano M, et al. Among authors: verrienti a. Endocrine. 2018 Jan;59(1):209-212. doi: 10.1007/s12020-017-1240-6. Epub 2017 Jan 24. Endocrine. 2018. PMID: 28120182 No abstract available.
63 results